TVM Capital Life Science is an international venture capital firm focused on life science innovations, investing in early-stage therapeutics and commercial-stage medtech, diagnostics, and digital health. The firm has offices in Munich, Germany and Montreal, Canada.
Average disclosed round size is $22.4M (across 8 rounds with reported amounts).
Portfolio
11
Fund Size
$478M
Top Stage
Series C
Last 12 Mo
0
Team
Dr. Hubert Birner
Managing Partner,Munich
Stefan Fischer
Managing Partner (Finance),Munich
Marc Rivière, MD
General Partner,Montreal
Josef Moosholzer
Partner Finance
Dr. Valentina Agostoni
Principal,Montreal
Ivan T. Shaw, PhD
Principal,Montreal
Pia Siegele
Senior Associate,Munich
Barbara Hauser
Senior Accountant
Mechthild Heinemann
Office Administration
Monika Marosevic
Accountant
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| EEgg Medical | Unknown | $14.3M | Jan 2025 |
 CSA Medical | Series D | $53M | Sep 2024 |
 Smart Reporting | Series C | — | Apr 2024 |
| EEgg Medical | Unknown | $13M | Jan 2022 |
 Access Vascular | Series B | $20M | Mar 2021 |
 Leon Nanodrugs | Series B | — | Apr 2020 |
| CCentogene Ag | Series A | — | Jun 2017 |
| Leon Nanodrugs | Series A | — | Jul 2015 |
 Colucid Pharmaceuticals | Series C | $37.1M | Jan 2015 |
| AAurka Pharma Inc | Unknown | $11M | — |
| VVektor Medical Inc | Series A | $16M | — |
| KKent Imaging Inc | Growth | $15M | — |
 Emovi | Series C | — | — |
Top Co-Investors
Last updated: 20 October 2026